ClinicalTrials.gg
Active, not recruitingNCT06226714Updated Jul 29, 2025

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds

A Phase 3 interventional study of MCV4 and MPSV4 in Meningococcal Meningitis, sponsored by CanSino Biologics Inc.. Active, not recruiting at 3 sites in China. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by CanSino Biologics Inc. · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
840
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Meningitis, Meningococcal with a site in China — 5 open to participants now, 8 under way, 5 of them phase 3. Meningitis, Meningococcal · China.

Enrollment
10th of 19
840 · median 840
Started
2024
with 3 others
Phase 3
10 of 19
3 open now
Registered
11th of 19
by date
Lead sponsor
6 of 19
CanSino Biologics Inc.

Among the 19 studies in Meningitis, Meningococcal with a site in China, this one is the 10th largest by enrollment, is one of 4 that started in 2024, is one of 10 in phase 3, and was the 11th registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

5 of the 19 studies in Meningitis, Meningococcal with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Meningitis, Meningococcal with a site in China, or all of them as a file.
02

Study summary

This is a randomized, observer-blind, peer-controlled study. There will be 2 treatment groups, screened subjects were given study numbers in the order of enrollment and randomly assigned to the test and control groups in a 1:1 ratio. Subjects were required to complete a 1-dose immunization program with 0.5 ml of vaccine in both the test and control groups.

03

Conditions studied

  • Meningococcal Meningitis

Keywords

  • Vaccine
  • Peer controlled
  • Immunogenicity
  • Safety
  • 18-59 years
04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18\~59 years old at the time of screening.
  • Should not have received any meningococcal vaccine in the last 3 years.
  • Volunteers have given , have voluntarily signed an informed consent form, are able and willing to comply with the requirements of the clinical trial protocol, and are able to complete the 180-day study follow-up visit.
  • Volunteers have given informed consent, have voluntarily signed an informed consent form, are able and willing to comply with the requirements of the clinical trial protocol, and are able to complete the 180-day study follow-up visit.
  • Willingness to discuss medical history with the investigator or physician and to allow access to all medical records relevant to this trial.

Exclusion criteria

Exclusion Criteria:

  • Fever before vaccination, axillary temperature >37.0°C.
  • History of epilepsy, convulsions or seizures or history or family history of psychiatric disorders.
  • Volunteers with current meningitis or a history of meningitis.
  • Blood pregnancy-positive or breastfeeding women with a planned pregnancy within 180 days of the volunteer or her partner.
  • to an ingredient or of the medicinal product used in this clinical trial (mainly: group A meningococcal podophyllotoxin, group C meningococcal podophyllotoxin, group Y meningococcal podophyllotoxin, group W135 meningococcal podophyllotoxin, sucrose, mannitol, sodium chloride, dipotassium hydrogen phosphate trihydrate, potassium dihydrogen phosphate).
  • Severe hypertension uncontrolled by medication (at on-site measurement: systolic blood pressure ≥ 160 mmHg, diastolic blood pressure ≥ 100 mmHg).
  • Previous vaccination-related hospitalizations or emergencies.
  • Bleeding constitution or condition associated with prolonged bleeding that investigators consider for intramuscular injection.
  • Other vaccinations within 14 days.
  • Participation in other studies involving interventional studies within 28 days prior to study entry (\<28 days) and/or during study participation.
  • Other circumstances that, in the judgment of the investigator, make participation in this clinical trial inappropriate.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
840 participants (actual)

Study arms

  • Experimental
    ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (MCV4)

    Intramuscular injection, 0.5ml

    Biological: MCV4

  • Active comparator
    ACYW135 Group Meningococcal Polysaccharide Vaccine (MPSV4)

    Subcutaneous iniection, 0.5ml

    Biological: MPSV4

Interventions

  • BiologicalMCV4

    1 dose of MCV4 on Day 0

  • BiologicalMPSV4

    1 dose of MSPV4 on Day 0

06

What researchers measure

Primary outcomes

  1. Meningococcal antibody positive conversion rates for groups A, C, Y, and W135 in all subjects

    Time frame: 30 days post immunization

  2. Geometric mean titer (GMT) of antibodies to groups A, C, Y, and W135 in all subjects

    Time frame: 30 days post immunization

  3. Incidence of adverse reactions in all subjects

    Time frame: Within 30 mins after immunization

  4. Incidence of adverse reactions/events in all subjects

    Time frame: 7 days post immunization

  5. Incidence of adverse reactions/events in all subjects

    Time frame: Within 30 days after immunization

Secondary outcomes

  1. Meningococcal antibody positivity for groups A, C, Y, and W135

    Time frame: 30 days post immunization

  2. Geometric mean multiplicity (GMI) of increase for groups A, C, Y, and W135

    Time frame: 30 days post immunization

  3. Antibody titer ≥1:128 ratio for groups A, C, Y, and W135

    Time frame: 30 days post immunization

  4. Meningococcal antibody positivity for groups A, C, Y, and W135 in selected subjects

    Time frame: 180 days after immunization

  5. GMT for groups A, C, Y, and W135 in selected subjects

    Time frame: 180 days after immunization

  6. GMI for groups A, C, Y, and W135 in selected subjects

    Time frame: 180 days after immunization

  7. Antibody titer ≥1:128 ratio for groups A, C, Y, and W135 in selected subjects

    Time frame: 180 days after immunization

  8. Incidence of serious adverse events (SAEs) in all subjects

    Time frame: Within 180 days after immunization

  9. Incidence of pregnancy events in all subjects

    Time frame: Within 180 days after immunization

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Sep 2024, 6 months.

Of 25 phase 3 interventional studies under Meningitis, Meningococcal, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 20. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2024
First posted
Jan 26, 2024
StartActual
Mar 1, 2024
Primary completionActual
Sep 26, 2024
CompletionEst.
Aug 2025
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06226714
Responsible party
Sponsor
First posted
Jan 26, 2024
Start date
Mar 1, 2024
Primary completion
Sep 26, 2024
Completion
Aug 2025 (estimated)
Last update
Jul 29, 2025

Study contacts

Qing Wang
principal investigator · Chongqing Center for Disease Control and Prevention

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion